• Non-Hodgkin’s Lymphoma Clinical Trials and Studies 2025: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Compani... The Globe and Mail Tue, 25 Mar 2025 07:00:00 GMT
• why is uber backing this tiny artificial intelligence (ai) company? The Globe and Mail Fri, 31 Jan 2025 18:29:18 GMT
• adaptimmune reports $41m q3 revenue, plans 33% staff cut to save $300m StockTitan Wed, 13 Nov 2024 08:00:00 GMT
• global t-cell therapy market trend [2024-2032] | consumer demographics WICZ Tue, 05 Nov 2024 03:15:00 GMT
• non-hodgkin’s lymphoma pipeline therapeutics, assessment, companies, products, unmet needs, market drivers and barriers The Globe and Mail Mon, 04 Nov 2024 22:31:36 GMT
• non-hodgkin lymphoma pipeline therapeutics, assessment, companies, products, unmet needs, market drivers and barriers The Globe and Mail Wed, 30 Oct 2024 15:02:46 GMT
• (til) tumour-infiltrating lymphocyte therapy market size to GlobeNewswire Fri, 23 Aug 2024 07:00:00 GMT
• car t-cell therapy market size is set to grow by usd 3.02 billion from 2024-2028, growing awareness regarding car t-cell therapy t... The Malaysian Reserve Sat, 06 Jul 2024 07:00:00 GMT
• car t-cell therapy market size is set to grow by usd 3.02 billion from 2024-2028, growing awareness regarding car t-cell therapy t... The Malaysian Reserve Fri, 05 Jul 2024 20:05:36 GMT
• companies like tcr2 therapeutics (nasdaq:tcrr) are in a position to invest in growth Yahoo Movies Canada Sun, 05 May 2024 13:26:11 GMT
• companies like tcr2 therapeutics (nasdaq:tcrr) could be quite risky Yahoo Lifestyle UK Wed, 10 Apr 2024 16:26:57 GMT
• tcr2 therapeutics files for mixed shelf offering of up to $300 mln Reuters.com Wed, 06 Mar 2024 08:00:00 GMT
• tcr2 leases ex-autolus plant in maryland - bioprocess insider BioProcess Insider Sun, 03 Mar 2024 02:51:06 GMT
• malignant pleural mesothelioma market is expected to grow at a cagr of 5.7% during the study period 2019-2032 ... 매일세종 Thu, 29 Feb 2024 13:21:36 GMT
• AstraZeneca To Invest $300M In Rockville Manufacturing Facility Bisnow Tue, 06 Feb 2024 08:00:00 GMT
• full year 2022 adaptimmune therapeutics plc earnings call transcript GuruFocus.com Tue, 06 Feb 2024 00:20:21 GMT
• adaptimmune therapeutics plc to discuss completion of strategic combination with tcr2 call transcript GuruFocus.com Tue, 06 Feb 2024 00:20:15 GMT
• the definitive boston biotech layoff tracker for 2023 The Business Journals Tue, 02 Jan 2024 08:00:00 GMT
• malignant pleural mesothelioma market growth anticipated by 2032 | major players: astrazeneca, pharmamar, polaris ... Industry Today Wed, 27 Dec 2023 10:19:52 GMT
• adaptimmune therapeutics plc (nasdaq:adap) q3 2023 earnings ... Yahoo Finance Mon, 13 Nov 2023 08:00:00 GMT
• t-cell therapy market size to grow usd us$ 76.6 billion from 2023 ... PR Newswire Mon, 06 Nov 2023 08:00:00 GMT
• healthcare moves: a monthly summary of hires and layoffs MedCity News Sun, 29 Oct 2023 07:00:00 GMT
• axicabtagene ciloleucel in combination with the 4–1bb agonist ... Cancer Discovery Fri, 13 Oct 2023 07:18:52 GMT
• bcl-xl targeting to induce apoptosis and to eliminate ... Cancer Discovery Thu, 12 Oct 2023 07:00:00 GMT
• diffuse large b-cell lymphoma market to show immense growth by ... GlobeNewswire Tue, 19 Sep 2023 07:00:00 GMT
• herthena-lung01, a phase ii trial of patritumab deruxtecan ... ASCO Journals Sun, 10 Sep 2023 07:00:00 GMT
• foghorn therapeutics names quintás-cardama chief medical officer Contract Pharma Fri, 08 Sep 2023 07:00:00 GMT
• Convergent Therapeutics Expands Leadership Team with the Appointments of Neil Bander, MD. as Chief Scientific Officer, Eric M. Sul... PR Newswire Wed, 06 Sep 2023 07:00:00 GMT
• adaptimmune reports second quarter financial results and business update Yahoo Finance Wed, 09 Aug 2023 07:00:00 GMT
• car t-cell therapy market size to grow at a cagr of 13.44% from ... Yahoo Finance Wed, 09 Aug 2023 07:00:00 GMT
• ankyra therapeutics appoints robert v. tighe, an accomplished industry veteran, as chief scientific officer Business Wire Mon, 07 Aug 2023 07:00:00 GMT
• Mesothelin-targeting T cell receptor fusion construct cell therapy in refractory solid tumors: phase 1/2 trial interim results Nature Thu, 27 Jul 2023 07:00:00 GMT
• Cartesian Therapeutics Advancing RNA-Based CAR-T in Myasthenia Gravis After Promising Early Data Precision Medicine Online Thu, 06 Jul 2023 07:00:00 GMT
• quell’s treg approach lands $2b astrazeneca deal to focus on ibd, type 1 diabetes BioWorld Online Mon, 19 Jun 2023 07:00:00 GMT
• quell's treg approach lands $2b astrazeneca deal to focus on ibd, type 1 diabetes BioWorld Online Mon, 19 Jun 2023 07:00:00 GMT
• first-in-human, phase i dose-escalation and dose-expansion ... ASCO Journals Fri, 16 Jun 2023 07:00:00 GMT
• mirvetuximab soravtansine yields disease reduction in frα+ ... Cancer Network Sun, 04 Jun 2023 07:00:00 GMT
• phase ii, open-label study of encorafenib plus binimetinib in ... ASCO Journals Sun, 04 Jun 2023 07:00:00 GMT
• Adaptimmune Announces Completion of Strategic Combination with TCR2 Therapeutics Creating a Preeminent Solid Tumor Cell Therapy Co... Yahoo Finance Thu, 01 Jun 2023 07:00:00 GMT
• adaptimmune therapeutics plc completed the acquisition of tcr2 therapeutics inc. from a group of shareholders. Marketscreener.com Thu, 01 Jun 2023 07:00:00 GMT
• adaptimmune completes merger with fellow immunology company tcr2 (adap) Seeking Alpha Thu, 01 Jun 2023 07:00:00 GMT
• who are the leading innovators in t-cell receptor peptides for the ... Pharmaceutical Technology Mon, 15 May 2023 07:00:00 GMT
• tcr² therapeutics reports first quarter 2023 financial results and provides corporate update Yahoo Finance Thu, 11 May 2023 07:00:00 GMT
• tcr² therapeutics reports inducement grants under nasdaq listing rule 5635(c)(4) Yahoo Finance Mon, 08 May 2023 07:00:00 GMT
• impact of biomarker-matched therapies on outcomes in patients ... Cancer Discovery Mon, 01 May 2023 08:09:08 GMT
• tcr² therapeutics announces pipeline priorities for 2023 GlobeNewswire Mon, 01 May 2023 07:00:00 GMT
• shareholder investigation: halper sadeh llc investigates focs, rocc, tcrr Marketscreener.com Thu, 27 Apr 2023 07:00:00 GMT
• long-term outcomes and molecular correlates of sotorasib ... ASCO Journals Tue, 25 Apr 2023 07:00:00 GMT
• adaptimmune shareholders can lock in a big merger spread by swapping to tcr2 Seeking Alpha Fri, 21 Apr 2023 07:00:00 GMT
• a slippery slope: basic research underfunded in australia, says study Phys.org Thu, 20 Apr 2023 07:00:00 GMT
• a slippery slope - basic research underfunded in australia The University of Queensland Wed, 19 Apr 2023 07:00:00 GMT
• shareholder update: halper sadeh llc investigates rocc, kbal, adap, tcrr Marketscreener.com Tue, 11 Apr 2023 07:00:00 GMT
• gsk outlines deal to send cell therapies back to adaptimmune BioPharma Dive Tue, 11 Apr 2023 07:00:00 GMT
• updated: quince adopts 'poison pill' to fend off buyout bid as ... FierceBiotech Thu, 06 Apr 2023 07:00:00 GMT
• pipeline moves: regeneron terminates pancreatitis trial, advancement prospects drop Clinical Trials Arena Tue, 04 Apr 2023 07:00:00 GMT
• biotech layoffs 2023: about 1,500 mass. workers were laid off in q1 The Business Journals Mon, 03 Apr 2023 07:00:00 GMT
• biotech layoffs 2023: about 1500 mass. workers were laid off in q1 - boston business journal The Business Journals Mon, 03 Apr 2023 07:00:00 GMT
• tcr² therapeutics reports inducement grants under nasdaq listing rule 5635(c)(4) TradingView Mon, 03 Apr 2023 07:00:00 GMT
• adaptimmune (adap): tcr2 merger represents opportunity for enthusiastic investors Seeking Alpha Sun, 26 Mar 2023 07:00:00 GMT
• adaptimmune: tcr2 merger represents opportunity for enthusiastic investors Seeking Alpha Sun, 26 Mar 2023 07:00:00 GMT
• new cell therapy company will treat solid tumours European Pharmaceutical Review Wed, 08 Mar 2023 08:00:00 GMT
• magrolimab in combination with azacitidine in patients with higher ... ASCO Journals Wed, 08 Mar 2023 08:00:00 GMT
• 5 Penny Stocks To Buy According To Analysts, Targets Up To 952% PennyStocks.com Tue, 07 Mar 2023 08:00:00 GMT
• march 6 quick takes: adaptimmune acquiring tcr2 therapeutics BioCentury Tue, 07 Mar 2023 08:00:00 GMT
• investigation alert: halper sadeh llc investigates radi, adap, tcrr, rocc Marketscreener.com Tue, 07 Mar 2023 08:00:00 GMT
• Adaptimmune absorbs TCR² to extend cash runway and broaden T-cell pipeline Fierce Biotech Mon, 06 Mar 2023 08:00:00 GMT
• Adaptimmune acquires struggling cell therapy rival following layoffs BioPharma Dive Mon, 06 Mar 2023 08:00:00 GMT
• Adaptimmune Therapeutics And TCR² Therapeutics To Merge (ADAP) (TCRR) Pulse 2.0 Mon, 06 Mar 2023 08:00:00 GMT
• adaptimmune, tcr2 therapeutics to combine in marriage of cell therapy developers MedCity News Mon, 06 Mar 2023 08:00:00 GMT
• adaptimmune agrees to merge with another cell therapy focused company Yahoo Finance Mon, 06 Mar 2023 08:00:00 GMT
• adaptimmune absorbs tcr² to extend cash runway, broaden pipeline Fierce Biotech Mon, 06 Mar 2023 08:00:00 GMT
• adaptimmune and tcr² therapeutics plan merger | the pharmaletter The Pharma Letter Mon, 06 Mar 2023 08:00:00 GMT
• shareholder alert: ademi llp investigates whether tcr² therapeutics inc. has obtained a fair price in its transaction ... Marketscreener.com Mon, 06 Mar 2023 08:00:00 GMT
• adaptimmune to acquire cell therapy company tcr² therapeutics - philadelphia business journal Philadelphia Business Journal Mon, 06 Mar 2023 08:00:00 GMT
• adaptimmune and tcr2 therapeutics announce strategic combination to create a preeminent cell therapy company for solid tumors Yahoo Finance Mon, 06 Mar 2023 08:00:00 GMT
• adaptimmune therapeutics plc entered into a definitive agreement to acquire tcr2 therapeutics inc. from a group of ... Marketscreener.com Sun, 05 Mar 2023 08:00:00 GMT
• systematic interrogation of tumor cell resistance to chimeric ... Cancer Discovery Fri, 17 Feb 2023 22:40:44 GMT
• tcr² therapeutics to present at svb securities global biopharma conference 2023 Yahoo Finance Wed, 08 Feb 2023 08:00:00 GMT
• layoffs continue to batter biotech, with big pharmas piling on the pain Fierce Biotech Wed, 01 Feb 2023 08:00:00 GMT
• celularity warns of layoffs for 'substantial portion' of its staff BioPharma Dive Fri, 27 Jan 2023 08:00:00 GMT
• tarlatamab, a first-in-class dll3-targeted bispecific t-cell ... ASCO Journals Mon, 23 Jan 2023 08:00:00 GMT
• a first-in-human phase i study of milademetan, an mdm2 inhibitor ... ASCO Journals Fri, 20 Jan 2023 08:00:00 GMT
• personalized bile duct cancer treatment improves prognosis The Science Board Thu, 19 Jan 2023 08:00:00 GMT
• TCR² removed 20% of staff over summer, paving way for latest layoffs Fierce Biotech Fri, 13 Jan 2023 08:00:00 GMT
• Fate, two other cell therapy biotechs lay off staff, restructure research BioPharma Dive Fri, 06 Jan 2023 08:00:00 GMT
• crispr layoffs 2023: job cuts hit gene-editing stocks fate, tcrr, ipsc InvestorPlace Fri, 06 Jan 2023 08:00:00 GMT
• TCR² Therapeutics Announces Pipeline Priorities for 2023 GlobeNewswire Thu, 05 Jan 2023 08:00:00 GMT
• tcr² therapeutics reports inducement grants under nasdaq listing rule 5635(c)(4) GlobeNewswire Thu, 05 Jan 2023 08:00:00 GMT
• astrazeneca inks $200m solid tumor tcr cell therapy buyout FierceBiotech Tue, 29 Nov 2022 08:00:00 GMT
• tcr² therapeutics to present at the piper sandler healthcare conference GlobeNewswire Wed, 23 Nov 2022 08:00:00 GMT
• three-year update of tisagenlecleucel in pediatric and young ... ASCO Journals Fri, 18 Nov 2022 08:00:00 GMT
• tcr² therapeutics reports third quarter 2022 financial results and provides corporate update Yahoo Finance Tue, 08 Nov 2022 08:00:00 GMT
• tcr² therapeutics presents preclinical data on functional GlobeNewswire Mon, 07 Nov 2022 08:00:00 GMT
• durvalumab with or without tremelimumab in combination with ... ASCO Journals Thu, 03 Nov 2022 07:00:00 GMT
• the top 25 healthcare technology leaders of san francisco for 2022 The Healthcare Technology Report. Tue, 01 Nov 2022 07:00:00 GMT
• t-cell therapy market size to hit $21+ billion with booming cagr ... GlobeNewswire Thu, 20 Oct 2022 07:00:00 GMT
• tcr² therapeutics reports inducement grants under nasdaq listing rule 5635(c)(4) GlobeNewswire Mon, 03 Oct 2022 07:00:00 GMT
• disarming the body's defenders | harvard medical school Harvard Medical School Thu, 29 Sep 2022 07:00:00 GMT
• TCR2's cell therapy racks up 22% response rate in heavily pretreated solid tumor patients Fierce Biotech Wed, 28 Sep 2022 07:00:00 GMT
• tcr2 therapeutics’ gavo-cel shows early promise in solid tumors, ovarian cancer BioSpace Wed, 28 Sep 2022 07:00:00 GMT
• tcr2 therapeutics stock rises 16% as cell therapy for solid tumors shows promise in trial Seeking Alpha Wed, 28 Sep 2022 07:00:00 GMT
• gavo-cel elicits clinical benefit in solid tumors, including ovarian cancer and mesothelioma OncLive Wed, 28 Sep 2022 07:00:00 GMT
• tcr2 therapeutics inc. : regulation fd disclosure, other events, financial statements and exhibits (form 8-k) Marketscreener.com Wed, 28 Sep 2022 07:00:00 GMT
• gavo-cel continues to demonstrate clinical benefit in solid tumors with additional recist reponses in ovarian ... GlobeNewswire Wed, 28 Sep 2022 07:00:00 GMT
• tcr² therapeutics to announce complete phase 1 portion of the gavo-cel phase 1/2 clinical trial for mesothelin ... GlobeNewswire Tue, 27 Sep 2022 07:00:00 GMT
• tcr² therapeutics to present at the jefferies cell & genetic medicine summit GlobeNewswire Mon, 26 Sep 2022 07:00:00 GMT
• ppf group | tcr2 therapeutics reported positive phase 1 data of its gavo-cel in solid tumors PPF Group Fri, 09 Sep 2022 07:00:00 GMT
• tcr2 therapeutics reported positive phase 1 data of its gavo-cel in solid tumors PPF Group Fri, 09 Sep 2022 07:00:00 GMT
• tcr2 therapeutics reports inducement grants under nasdaq listing rule 5635(c)(4) GlobeNewswire Thu, 01 Sep 2022 07:00:00 GMT
• harpoon therapeutics stock: cancer killing at a discount ... Seeking Alpha Thu, 01 Sep 2022 07:00:00 GMT
• patient-reported symptom burden in patients with rare cancers ... Nature.com Tue, 23 Aug 2022 07:00:00 GMT
• TCR² Pharmaceuticals: Betting On A Solid Reversal (NASDAQ:TCRR) Seeking Alpha Thu, 18 Aug 2022 07:00:00 GMT
• six-year results from relevance: lenalidomide plus rituximab ... ASCO Journals Wed, 10 Aug 2022 07:00:00 GMT
• what kind of shareholders hold the majority in tcr2 therapeutics inc.'s (nasdaq:tcrr) shares? Yahoo Finance Mon, 08 Aug 2022 07:00:00 GMT
• tcr² therapeutics reports inducement grants under nasdaq listing rule 5635(c)(4) GlobeNewswire Mon, 01 Aug 2022 07:00:00 GMT
• immunocore has a sip with usd140m private placement European Biotechnology News Tue, 19 Jul 2022 07:00:00 GMT
• escrt machinery: role of membrane repair mechanisms in ... Nature.com Sat, 16 Jul 2022 07:00:00 GMT
• tcr² therapeutics to present at the j.p. morgan healthcare conference GlobeNewswire Fri, 01 Jul 2022 07:00:00 GMT
• tcr² therapeutics reports inducement grants under nasdaq listing rule 5635(c)(4) GlobeNewswire Fri, 01 Jul 2022 07:00:00 GMT
• tcr² therapeutics appoints eric sullivan as chief financial officer citybiz Mon, 27 Jun 2022 07:00:00 GMT
• tcr² therapeutics appoints industry and finance veteran eric sullivan as chief financial officer Yahoo Finance Mon, 27 Jun 2022 07:00:00 GMT
• the munich biotech mafia expand to the us with a new tcr startup Labiotech.eu Wed, 22 Jun 2022 07:00:00 GMT
• new immuno-oncology partnership faces the challenges of solid tumors Labiotech.eu Wed, 22 Jun 2022 07:00:00 GMT
• phase ii study of venetoclax added to cladribine plus low-dose ... ASCO Journals Wed, 15 Jun 2022 07:00:00 GMT
• NMPA approved China’s first independently developed CAR-T therapy Relma-cel PPF Group Tue, 07 Jun 2022 06:15:23 GMT
• ppf group | nmpa approved china's first independently developed car-t therapy relma-cel PPF Group Tue, 07 Jun 2022 06:15:23 GMT
• nmpa approved china's first independently developed car-t therapy relma-cel PPF Group Tue, 07 Jun 2022 06:15:23 GMT
• three-year follow-up of kte-x19 in patients with relapsed ... ASCO Journals Sat, 04 Jun 2022 07:00:00 GMT
• tcr² therapeutics to participate in two upcoming conferences in june Yahoo Finance Wed, 01 Jun 2022 07:00:00 GMT
• beyond immunotherapy: new targeted agents for advanced nsclc The ASCO Post Wed, 25 May 2022 07:00:00 GMT
• tcr² therapeutics reports first quarter 2022 financial results and provides corporate update GlobeNewswire Thu, 12 May 2022 07:00:00 GMT
• basket trials: review of current practice and innovations for future ... ASCO Journals Tue, 10 May 2022 07:00:00 GMT
• cancer drug developers trade below liquid assets with no respite in sight Bloomberg Wed, 04 May 2022 07:00:00 GMT
• tcr2 therapeutics, arbor biotechnologies partner on truc-t cell therapies Contract Pharma Fri, 01 Apr 2022 07:00:00 GMT
TCR2 Therapeutics Inc(NASDAQ:TCRR) 
TCR2 Therapeutics Inc., a clinical-stage immunotherapy company, develops novel T cell receptor therapies for patients suffering from cancer. The company's lead product candidates include gavo-cel, a mono TCR Fusion Construct T cells (TRuC-T cells) targeting mesothelin positive solid tumors, which is...
Website: http://www.tcr2.com
Founded: 2015
Full Time Employees: 109
Sector: Healthcare
Industry: Biotechnology